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Qualitative differences due to track 
“core” and correlated tissue damage 
along particle path. (Plante, 2011)
DNA Damage
H2AX foci in 
EPC2-hTERT 
cells.
(Patel and Huff)
High LET defined as
LET > 10 keV/µm in tissue
1 GeV/u 56Fe nucleus 
LET∼150 keV/μm 
• Interplanetary crews will be exposed to a high 
LET radiation  environment comprised of high-
energy protons and heavy ions (HZEs) as well 
as secondary protons, neutrons, and fragments 
produced in shielding and tissue
• Heavy ions are qualitatively different from X-
rays or Gamma-rays: High LET vs. low LET
− Densely ionizing along particle track
− Cause unique damage to biomolecules, 
cells, and tissues
− Distinct patterns of DNA damage (mutation 
spectra, chromosome aberrations) and 
distinct profiles of oxidative damage
• No human data  exist to estimate risk from 
heavy ions found in space
– Animal and cellular models with simulated 
space radiation must be applied or 
developed
• Synergistic modifiers of risk from other 
spaceflight factors
Risk of Radiation Carcinogenesis
• Morbidity and mortality risks; major driver for PELs
Risk of Acute (in flight)  & Late Central Nervous 
System Effects
• Possible in-flight risks: altered cognitive function including short-term memory, 
reduced motor function, and behavioral changes which may affect 
performance and human health 
• Possible late (post-mission) risks: neurological disorders such as Alzheimer’s 
disease (AD), dementia, cerebrovascular disease or premature aging
Risk of Cardiovascular Disease and other 
Degenerative Tissue Effects
• Degenerative changes in the heart, vasculature, and lens
• Diseases related to aging, including digestive, respiratory disease, premature 
senescence, endocrine, and immune system dysfunction
Risk of Acute Radiation Syndromes due to Solar 
Particle Events
• Prodromal effects (nausea, vomiting, anorexia, and fatigue), skin injury, and 
depletion of the blood-forming organs
Radiotherapy Data:
• High doses ( >5 Gy exposures) associated 
with damage to the structures of the heart 
and to the coronary, carotid, and other large 
arteries including marked diffuse fibrotic 
damage, especially of the pericardium and 
myocardium, pericardial adhesions, 
microvascular damage and stenosis of the 
valves—damage observed in patients 
receiving RT as well as in experimental 
animals (Little 2013)
• Deterministic effect (tissue reaction)
• Mechanisms involve cell killing or 
inactivation of large # of cells – functional 
impairment
• Moderate doses (0.5-- 5 Gy exposures)  
associated with atherosclerosis; micro 
and macrovascular damage
• Possibly a stochastic reaction
• Mechanisms may involve inflammation 
and oxidative stress, endothelial 
dysfunction/senescence
Life Span Study, Clinical, and 
Occupational Exposures :
• Still, there is conflicting data even 
at moderate dose ranges
• The results of these 11 studies 
have not been published in a 
sufficiently uniform format to permit 
a formal heterogeneity test but still 
clear that there is substantial 
heterogeneity between them
• Other challenges for these types of 
analyses include dosimetry issues, 
and misclassification of 
pathologies/cause of death
Funnel plot of ERR/Sv versus SE of ERR for 4 main circulatory 
disease subtypes. Red line shows aggregate random-effects 
ERR estimate. 
Meta-Analysis of Low Dose Studies:
• Low doses (< 0.5 Gy)  associated with 
systemic effects, microvascular damage
• Possibly a stochastic reaction
• Mechanisms may involve non-targeted 
effects, kidney dysfunction, monocyte 
killing
• Confounding effects are large
 Although mean cumulative radiation doses were ≤ 0.2 Gy in most of studies, the 
small numbers of participants exposed at high cumulative doses (≥ 0.5 Gy) drive 
the observed trends in most cohorts with these higher dose groups
 Suggests increased risks for IHD and non-IHD heart diseases
 Data suggest that circulatory disease risk is significantly elevated only for 
acute or cumulative doses of about 0.5 Gy and above; data is not 
statistically significant at lower doses
• Confounding factors in epidemiology studies 
include (Lifestyle and genetic factors): male sex, 
family history, cigarette smoking, drinking, 
diabetes, high blood pressure, obesity, increased 
low-density lipoprotein cholesterol, and decreased 
high-density lipoprotein cholesterol plasma levels; 
shift work
• Risk at lower doses and low dose rates still highly 
uncertain; existence of threshold dose 
questionable
• There is also a lack of data on dose rate effects
• Atomic bomb survivor data and analyses of epidemiology data provide evidence for elevation of 
risk at lower doses than previously identified, with significant risks at doses as low as 0.5 Gy
‒ Data at low doses is confounded by life-style factors, clouding interpretation of 
epidemiology data below 0.5 Gy
‒ Effects are considered deterministic, with an associated threshold dose; however 
recent evidence showing risk at lower doses questions this assumption
• Preliminary risk assessment models being formulated based on recent epidemiology data for 
lower dose low-LET exposures - future risk estimates dependent on research results describing 
the quantitative and qualitative differences between GCR and gamma-rays
– Studies at NSRL with HZE ions and appropriate animals models are required
– Lack of evidence on radiation quality, disease spectrum, latency and dose rate at 
low levels of exposures
• The additional mortality and morbidity risks for non-cancer diseases of the 
cardiovascular system are major concerns because they could increase REID values 
substantially
• Association between exposure to high doses of low-LET (>5 Gy) radiation during 
radiotherapy to the chest and increased risk for development of cardiovascular disease at late 
times post exposure is clearly established
• Tuberculosis patients in Canadian Fluoroscopy Cohort Study
• 63,707 patients (61% unexposed, 96% <0.5 Gy, mean dose=0.79 Gy)
 ERR/Gy=0.176 for IHD after adjustment for dose fractionation. ERR/Gy=0.149 for doses 
<0.5 Gy
 Highest risks were for those with fewest fluoroscopic procedures per year
International Space Station
• 2013-2020: 6-person crews, 180 days (nominal); 2-person crew 360 days in 
planning 
• Approach limits for acceptable radiation risks after 1 to 3 missions
Lagrange Points
• Design Reference Mission currently being formulated
• Outside Earth’s magnetosphere and radiation belts
• Galactic cosmic ray risks are major concern
Near Earth Objects
• Design Reference Mission currently being formulated
• Outside Earth’s magnetosphere and radiation belts
• Galactic cosmic ray risks are major concern
Mars
• 2030 and beyond: 6-person crews, up to 1000 days
• Long deep space transit times
• Risks exceed NASA Permissible Exposure Limits (PELs) for cancer, and 
pose significant non-cancer risks 
• Previous NCRP 2000 Report defined a “threshold dose” as an exposure below which clinically 
significant effects do not occur
• ICRP 2012 redefined “threshold dose” as ED1 (estimated dose for 1% incidence), denoting the 
amount of radiation that is required to cause a specific, observable effect in only 1% of individuals 
exposed to radiation. 
– ED1 = effects just starting to rise above the baseline levels in unirradiated, age-matched 
individuals and, in the case of circulatory disease, to a dose which would increase the 
already high natural incidence or mortality by only 1%. 
• ED1 does not imply that no biological effects occur at lower doses; it merely defines the dose above 
which a specified effect becomes clinically apparent in a small percentage of individuals.
 0.5 Gy may lead to approximately 1% of exposed individuals 
developing the disease in question >10 years after exposure. This is 
in addition to the high natural incidence rate (circulatory diseases account 
for 30–50% of all deaths in most developed countries).
The Space Radiation Problem
Health Risks from Space Radiation
Risk of Degenerative Tissue Effects:
• Cardiovascular and circulatory changes
• Cataract formation
Other Health Effects:
• Diseases related to aging, including digestive, respiratory disease, 
premature senescence, endocrine, and immune system 
dysfunction
Driving Evidence:
• Astronaut data (cataracts)
• Radiotherapy, environmental disasters, atomic bomb survivor 
data, radiation workers (CVD and others)
− Data is confounded by life-style factors to larger extent than 
cancer, especially at low doses
Risk Projections:
• Preliminary risk assessment models being formulated
• Recent studies suggest there may be low dose effects and distinct 
pathologies at low vs high dose suggesting mechanistic differences
• Impact of heavy ions largely unknown
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Aortic lesions in apoE-/- mice after 
56Fe irradiation (Kucik 2011).
Cardiovascular Disease and Other 
Degenerative Tissue Effects from Radiation
Definition of “Threshold Dose”:
ICRP Recommendations (2012)
High Doses > 5 Gy
Moderate Doses 0.5 - 5 Gy
Low Doses < 0.5 Gy
Low Dose Confounders & Uncertainties
Potential Mechanisms of Radiation-Induced CVD
Potential Mechanisms for Exposures at Moderate Doses
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